Global Combined Hormonal Contraceptive Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Combined Hormonal Contraceptive Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Combined hormonal contraceptive basically made by a combination of an estrogen and a progestogen which are primarily used to prevent unwanted pregnancies. Combined hormonal contraceptives are one of the effective contraceptives in modern medicine. Since late 1950s variety of innovation has been developed to improve the efficacy and safety of combined hormonal contraceptive. The trends have been shifted towards less androgenic progestogens and lower doses of estrogen and progestogen. Changing in drug doses and modification in drug component with the incorporation of new technologies that can reduce the risk factor and the continuing development of novel delivery systems that can be helpful to fulfill unmet needs of the market. The other health benefits of combined hormonal contraceptives include they reduce the risk of iron deficiency anemia, endometriosis, used in treating acne vulgaris, irregular menstrual flow, and polycystic ovarian syndrome. The mechanism of combined hormonal contraceptive is inhibition of follicle stimulating hormone and luteinizing hormone. Ethinylestradiol is the most common estrogen used in combined hormonal contraceptives, whereas other hormones are also used. The combined hormonal contraceptive products are available in various forms whereas pills have the maximum share in the combined hormonal contraceptive market. According to the Association of Women Health, around 100 million women use combined hormonal contraceptives throughout the world.
The global Combined Hormonal Contraceptive market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The growth of the combined hormonal contraceptive market is driven by growing predominance and more productive medications with emerging interest in quick substitutes. Reduction in the cost of hospitalization and high efficacy can be the prime driving factors for the growth of the combined hormonal contraceptive market over the forecast period. In emerging countries, the adoption of combined hormonal contraceptives has increased, along with increasing health consciousness and awareness. Growing menstruating population worldwide and various initiatives taken by the governments, such as birth control and women health awareness programs, are factors expected to increase the usage of combined hormonal contraceptive products globally. Strategic collaborations and acquisitions among manufacturers are also expected to boost the growth of the combined hormonal contraceptive market. However, side effects related to the combined hormonal contraceptive products can hamper the growth of the combined hormonal contraceptive market.
In terms of sales (consumption) side, this report focuses on the sales of Combined Hormonal Contraceptive by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Combined Hormonal Contraceptive market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Combined Hormonal Contraceptive market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Actavis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Watson Pharma
Cipla
Novartis International
By Type
Pills
Patch
Ring
By Application
Hospital Pharmacies
Retail Pharmacies
E-commerce
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Combined Hormonal Contraceptive in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Combined Hormonal Contraceptive manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Combined Hormonal Contraceptive sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
The global Combined Hormonal Contraceptive market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The growth of the combined hormonal contraceptive market is driven by growing predominance and more productive medications with emerging interest in quick substitutes. Reduction in the cost of hospitalization and high efficacy can be the prime driving factors for the growth of the combined hormonal contraceptive market over the forecast period. In emerging countries, the adoption of combined hormonal contraceptives has increased, along with increasing health consciousness and awareness. Growing menstruating population worldwide and various initiatives taken by the governments, such as birth control and women health awareness programs, are factors expected to increase the usage of combined hormonal contraceptive products globally. Strategic collaborations and acquisitions among manufacturers are also expected to boost the growth of the combined hormonal contraceptive market. However, side effects related to the combined hormonal contraceptive products can hamper the growth of the combined hormonal contraceptive market.
In terms of sales (consumption) side, this report focuses on the sales of Combined Hormonal Contraceptive by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Combined Hormonal Contraceptive market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Combined Hormonal Contraceptive market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Actavis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Watson Pharma
Cipla
Novartis International
By Type
Pills
Patch
Ring
By Application
Hospital Pharmacies
Retail Pharmacies
E-commerce
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Combined Hormonal Contraceptive in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Combined Hormonal Contraceptive manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Combined Hormonal Contraceptive sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.